CN Patent

CN117279915A — Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法

Assigned to Aclaris Therapeutics Inc · Expires 2023-12-22 · 2y expired

What this patent protects

本公开涉及用于使用局部制剂治疗由免疫缺陷引起的皮肤紊乱的方法，所述局部制剂包括(R)‑4‑((1‑(2‑氰基乙酰基)哌啶‑3‑基)氨基)‑1H‑吡咯并[2,3‑b]吡啶‑5‑羧酸乙酯(化合物I)或其药学上可接受的衍生物。特别地，本文所描述的局部制剂可以被用于治疗特异性皮炎、斑秃或白癜风。

USPTO Abstract

本公开涉及用于使用局部制剂治疗由免疫缺陷引起的皮肤紊乱的方法，所述局部制剂包括(R)‑4‑((1‑(2‑氰基乙酰基)哌啶‑3‑基)氨基)‑1H‑吡咯并[2,3‑b]吡啶‑5‑羧酸乙酯(化合物I)或其药学上可接受的衍生物。特别地，本文所描述的局部制剂可以被用于治疗特异性皮炎、斑秃或白癜风。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN117279915A
Jurisdiction: CN
Classification: —
Expires: 2023-12-22
Drug substance claim: No
Drug product claim: No
Assignee: Aclaris Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.